B
Bull
Bull · 25%RVPH
$0.41
Precio del escenario
$0.352
-0.196 (-55.73%)Al cierre
Loading chart…
- High
- 0.444
- Open
- 0.332
- VWAP
- 0.35
- Vol
- 13.18M
- Mkt Cap
- 38.17M
- Low
- 0.262
- Amount
- 4.65M
- EV/EBITDA, TTM
- 0.00
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
AI analysis of Reviva Pharmaceuticals Holdings Inc (RVPH)
sellRVPH is not a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is in a severe downtrend, the company is facing financing and listing risk, analysts have turned more cautious, and the current share price is far below key technical levels. Even though there are a few long-term pipeline positives, the balance of evidence says to avoid buying this stock now.
Métricas de valoración
The current forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) is 0.00, compared to its 5-year average forward P/E of -2.54.
Alphio AI Price Scenarios for RVPH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-12NewsfilterReviva Pharmaceuticals Files Patent for New Brilaroxazine to Extend Exclusivity Through 2046
1.006-26GlobenewswireVirtual Investor Conferences Forum Highlights
- 1.006-23Globenewswire
Agenda Announced for Life Sciences Virtual Investor Forum
9.505-13seekingalphaReviva Pharmaceuticals Q1 Earnings Miss Expectations
- 8.505-13Newsfilter
Reviva Pharmaceuticals Files New Patent to Extend Commercial Exclusivity to 2046
RVPH FAQ — answered by Alphio AI
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
RVPH is not a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is in a severe downtrend, the company is facing financing and listing risk, analysts have turned more cautious, and the current share price is far below key technical levels. Even though there are a few long-term pipeline positives, the balance of evidence says to avoid buying this stock now.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.